RCR reacts to prostate cancer screening recommendation
The UK National Screening Committee has recommended introducing prostate cancer screening only for men between the ages of 45 and 61 who have mutations of the BRCA1 and BRCA2 genes, every two years.
Responding to the recommendation, Dr Stephen Harden, President of the Royal College of Radiologists, said:
“Targeted prostate cancer screening is an important step to catch cancer earlier and help improve outcomes for those at higher risk as BRCA gene carriers. However, it will increase demand for MRI and other diagnostic imaging, and for clinical assessment and treatment.
We must train up more clinical radiologists and clinical oncologists to ensure that additional cases detected through screening can be assessed, monitored, and treated promptly and effectively. Many people diagnosed through screening may enter long term monitoring or have treatment with lasting side effects. Supportive oncology services should be expanded to help more patients access support for the physical, emotional, and practical impact of their diagnosis.
We look forward to the results of the TRANSFORM targeted screening trial which will provide further data on the risks and benefits of extending screening.
We will continue our work with policymakers to advocate for timely diagnosis and improved cancer outcomes for patients across the UK.”
- Media contact: [email protected] 02038054065
- The Royal College of Radiologists (RCR) is the leading professional membership body for clinical radiologists and clinical oncologists
- Clinical radiologists are specialist doctors who use imaging to diagnose, monitor and treat diseases and injuries
- Clinical oncologists are specialist doctors who manage cancer and prescribe drug-based treatments and radiotherapy
- Leading medical royal colleges representing senior cancer doctors, including the RCR, are calling for urgent investment in acute and supportive oncology services to stop the patient care postcode lottery